Taysha Gene Therapies Inc

$15.75 0.00% ($0.00)

Get ready to invest

About Taysha Gene Therapies Inc

Taysha Gene Therapies, Inc. is a gene therapy company focused on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. Its product candidates include: TSHA-101, which is being developed for the treatment of GM2 gangliosidosis; TSHA-118, which is a AAV9 viral vector that expresses human codon-optimized Ceroid Lipofuscinosis Neuronal 1 complementary deoxyribonucleic acid under control of the chicken b-actin hybrid promoter; TSHA-102, which is being developed for the treatment of Rett syndrome; TSHA-103, which is being developed for the treatment of Solute Carrier Family 6 Member 1 (SLC6A1) haploinsufficiency disorder, and TSHA-104, which is being developed for the treatment for Surfeit locus 1.

Popular Stocks	Price	Change
Snap SNAP	$55.14 8.44%	8.44%
Intel INTC	$49.46 0.7%	0.7%
Itau ITUB	$4.13 0.24%	0.24%
Petrobras PBR	$9.95 1.64%	1.64%
Banco Bradesco Pref Shares BBD	$3.6 1.64%	1.64%
Ford F	$16.28 0.31%	0.31%
Cleveland-Cliffs CLF	$23.85 7.19%	7.19%
Apple AAPL	$148.69 0.52%	0.52%
Ambev ABEV	$2.62 1.95%	1.95%